ID   MCF-7/4-HC
AC   CVCL_4V53
SY   MCF-7/4-hc; MCF7/4HC; MCF-7/OAP
DR   cancercelllines; CVCL_4V53
DR   Wikidata; Q54904348
RX   PubMed=3180059;
RX   PubMed=8328987;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:196991; 4-hydroperoxycyclophosphamide.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 13
//
RX   PubMed=3180059;
RA   Frei E. 3rd, Teicher B.A., Holden S.A., Cathcart K.N.S., Wang Y.-Y.;
RT   "Preclinical studies and clinical correlation of the effect of
RT   alkylating dose.";
RL   Cancer Res. 48:6417-6423(1988).
//
RX   PubMed=8328987; DOI=10.1016/0006-2952(93)90231-K;
RA   Sreerama L., Sladek N.E.;
RT   "Identification and characterization of a novel class 3 aldehyde
RT   dehydrogenase overexpressed in a human breast adenocarcinoma cell line
RT   exhibiting oxazaphosphorine-specific acquired resistance.";
RL   Biochem. Pharmacol. 45:2487-2505(1993).
//